Cypress Asset Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Cypress Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-6,240	Closed	-$226K	–	212
2016 Q4	$226K	Sell	6,240 -400	-6%	-$16K	0.04%	198
2016 Q3	$306K	Sell	6,640 -200	-3%	-$10.4K	0.06%	169
2016 Q2	$344K	Hold	6,840	–	–	0.07%	158
2016 Q1	$366K	Sell	6,840 -810	-11%	-$47.5K	0.07%	154
2015 Q4	$502K	Sell	7,650 -125	-2%	-$7.72K	0.1%	134
2015 Q3	$439K	Hold	7,775	–	–	0.09%	137
2015 Q2	$460K	Buy	7,775 +150	+2%	+$9.25K	0.09%	143
2015 Q1	$475K	Buy	7,625 +75	+1%	+$4.36K	0.09%	137
2014 Q4	$434K	Buy	7,550 +200	+3%	+$11.1K	0.08%	149
2014 Q3	$395K	Sell	7,350 -100	-1%	-$5.3K	0.07%	155
2014 Q2	$391K	Hold	7,450	–	–	0.07%	160
2014 Q1	$394K	Hold	7,450	–	–	0.07%	151
2013 Q4	$299K	Sell	7,450 -200	-3%	-$7.88K	0.05%	164
2013 Q3	$289K	Sell	7,650 -14,375	-65%	-$561K	0.05%	158
2013 Q2	$863K	Buy	+22,025	New	+$858K	0.16%	108

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Cypress Asset Management's TEVA Position: Q1 2017 in Review

Cypress Asset Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q1 2017, closing a stake of 6,240 shares — an estimated $226K sold.

Cypress Asset Management first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $863K in Q2 2013. 688 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

Cypress Asset Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q1 2017 after selling out during the quarter.
Cypress Asset Management sold 6,240 Teva Pharmaceutical Industries Limited shares in Q1 2017, an estimated $226K.
Cypress Asset Management first reported a position in Teva Pharmaceutical Industries Limited in Q2 2013 and held it in 15 quarters.
Cypress Asset Management's Teva Pharmaceutical Industries Limited position peaked at $863K in Q2 2013.
688 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2017.

Based on Cypress Asset Management's 13F filing for Q1 2017, filed 12 May 2017.